Real-world effectiveness and factors associated with effectiveness of inactivated SARS-CoV-2 vaccines: a systematic review and meta-regression analysis

• Published in: BMC medicine 2023-04, Vol.21 (1), p.160-160, Article 160
• Main Authors: Xu, Shiyao, Li, Jincheng, Wang, Hongyuan, Wang, Fuzhen, Yin, Zundong, Wang, Zhifeng
• Format: Article
• Language: English
• Subjects: Bias; China; Clinical trials; Cohort analysis; Control; Coronaviruses; Cost benefit analysis; COVID-19 - prevention & control; COVID-19 Vaccines; Deactivation; Effectiveness; Epidemics; Estimates; Factor; Hospitalization; Humans; Immunization; Inactivated vaccine; Infections; Information theory; Meta-analysis; Meta-regression; Methods; Pandemics; Population studies; Prevention; Regression Analysis; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Systematic review; Vaccine efficacy; Vaccines; Vaccines, Inactivated; Viral diseases; Viruses
• ISSN: 1741-7015; 1741-7015
• DOI: 10.1186/s12916-023-02861-3

The two inactivated SARS-CoV-2 vaccines, CoronaVac and BBIBP-CorV, have been widely used to control the COVID-19 pandemic. The influence of multiple factors on inactivated vaccine effectiveness (VE) during long-term use and against variants is not well understood. We selected published or preprinted articles from PubMed, Embase, Scopus, Web of Science, medRxiv, BioRxiv, and the WHO COVID-19 database by 31 August 2022. We included observational studies that assessed the VE of completed primary series or homologous booster against SARS-CoV-2 infection or severe COVID-19. We used DerSimonian and Laird random-effects models to calculate pooled estimates and conducted multiple meta-regression with an information theoretic approach based on Akaike's Information Criterion to select the model and identify the factors associated with VE. Fifty-one eligible studies with 151 estimates were included. For prevention of infection, VE associated with study region, variants, and time since vaccination; VE was significantly decreased against Omicron compared to Alpha (P = 0.021), primary series VE was 52.8% (95% CI, 43.3 to 60.7%) against Delta and 16.4% (95% CI, 9.5 to 22.8%) against Omicron, and booster dose VE was 65.2% (95% CI, 48.3 to 76.6%) against Delta and 20.3% (95% CI, 10.5 to 28.0%) against Omicron; primary VE decreased significantly after 180 days (P = 0.022). For the prevention of severe COVID-19, VE associated with vaccine doses, age, study region, variants, study design, and study population type; booster VE increased significantly (P = 0.001) compared to primary; though VE decreased significantly against Gamma (P = 0.034), Delta (P = 0.001), and Omicron (P = 0.001) compared to Alpha, primary and booster VEs were all above 60% against each variant. Inactivated vaccine protection against SARS-CoV-2 infection was moderate, decreased significantly after 6 months following primary vaccination, and was restored by booster vaccination. VE against severe COVID-19 was greatest after boosting and did not decrease over time, sustained for over 6 months after the primary series, and more evidence is needed to assess the duration of booster VE. VE varied by variants, most notably against Omicron. It is necessary to ensure booster vaccination of everyone eligible for SARS-CoV-2 vaccines and continue monitoring virus evolution and VE. PROSPERO, CRD42022353272.